Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Interpace Biosciences Inc IDXG

Healthcare
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.


OTCQX:IDXG - Post by User

Interpace Biosciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by highshooteron Aug 16, 2017 2:58pm
121 Views
Post# 26588858

check this news

check this news

Wed Aug 16 14:23:28 2017 EDT

 

 02:23 PM EDT, 08/16/2017 (MT Newswires) -- Interpace Diagnostics Group (IDXG) shares surged more than 37% intraday after the company said UnitedHealthcare's (UNH) Oxford Health Plans is covering its ThyraMIR test for indeterminate thyroid nodules, effective Aug. 1. Oxford Health Plans offers health care benefits to employers and individuals primarily in New York, New Jersey, and Connecticut making it one of the largest health plans in the heavily populated tri-state region. Interpace Diagnostics said that with the addition of Oxford's members, the test is now covered for over 250 million lives nationwide, including through Medicare, national, and regional health plans. Price: 1.47, Change: +0.39, Percent Change: +36.11
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities